PRVB News and Press, Provention Bio Inc. From 11/09/19

Provention Bio, Inc. (PRVB) Q3 2019 Earnings Conference Call November 5, 2019 04:30 PM ET Company Participants Sam Martin - Investor Relations Andrew Drechsler - Chief Financial Officer Ashleigh Palmer - Co-Founder and Chief Executive Officer Francisco Leon - Co-Founder and Chi...

There are plenty of exciting areas in the biotech world for investors to consider right now. One of the most promising niches is in the world of diabetes treatments, where a number of biotech companies are on the cusp of developing new solutions to the disease. There are 425 million adults world...

Provention Bio (NASDAQ: PRVB ): Q3 GAAP EPS of -$0.24 beats by $0.05 . More news on: Provention Bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

OLDWICK, N.J. , Nov. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2019. "The...

OLDWICK, N.J. , Oct. 29, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its third quarter 2019 financial results on Tuesday, Novembe...

Point Roberts, WA and Delta, BC - October 28, 2019 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource covering pharmaceutical and biotech stocks releases a sector snapshot reporting on the growth of the global monoclonal antibody market and how this is affecting ind...

OLDWICK, N.J. , Oct. 24, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the European Medicines Agency (EMA) has granted PRV-031 (teplizumab) PRIori...

A Phase 2a clinical trial, PRINCE , evaluating Provention Bio's (NASDAQ: PRVB ) PRV-6527 , a small molecule oral inhibitor of CSF-1R in-licensed from Janssen Pharmaceutical Company, in 93 patients with moderate-to-severe Crohn's disease who were either naïve to biologic therapy o...

OLDWICK, N.J. , Oct. 22, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced top-line results from its randomized, placebo-controlled Phase 2a PRINCE clinical...

Provention Bio ( PRVB ) is a speculative biotech that you should definitely look into for the coming months. That's because there are a lot of moving parts for this biotech that could provide significant upside for investors. That's because the goal is for the biotech to meet with the FDA in...